Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of opevesostat versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer after prior hormonal therapy and taxane chemotherapy
NL-OMON59972Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Merck & Co. Primary endpoints: Overall Survival in AR LBD mutation-positive participants and Overall Survival in AR LBD mutation-negative participants. Started Apr 2024; status: recruiting.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON59972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59972.